NCT04184063View on ClinicalTrials.gov

Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 16, 2019

Primary Completion Date

July 30, 2020

Study Completion Date

June 30, 2021

Conditions
Progressive Supranuclear PalsyMultiple System Atrophy
Interventions
DRUG

NBMI

NBMI active treatment

OTHER

Placebo

Placebo for comparison

Trial Locations (1)

1000

Ukc Ljubljana, Ljubljana

Sponsors

Lead Sponsor

EmeraMed
All Listed Sponsors
lead

EmeraMed

INDUSTRY

NCT04184063 - Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA) | Biotech Hunter | Biotech Hunter